Mutations of CARD11 but not TNFAIP3 may activate the NF-kappa B pathway in primary CNS lymphoma

作者：Montesinos Rongen Manuel^*; Schmitz Roland; Brunn Anna; Gesk Stefan; Richter Julia; Hong Ke; Wiestler Otmar D; Siebert Reiner; Kueppers Ralf; Deckert Martina

来源：Acta Neuropathologica, 2010, 120(4): 529-535.

DOI：10.1007/s00401-010-0709-7

• PCNSL
• NF-kappa B
• CARD11
• TNFAIP3
• Somatic mutation

Primary CNS lymphoma (PCNSL), the intracerebral subgroup of diffuse large B cell lymphoma (DLBCL), shows evidence for aberrant activation of the nuclear factor (NF)-kappa B pathway. In order to identify potential activators of the NF-kappa B complex, we analyzed the CARD11 and TNFAIP3 genes for the presence of somatic mutations and TNFAIP3 for aberrant promoter methylation in PCNSL. We also compared PCNSL to spinal DLBCL, because CARD11 and TNFAIP3 mutations have been described in systemic DLBCL. CARD11 mutations, located in the coiled-coil region, which may activate NF-kappa B, were detected in 16% (5/32) of PCNSL, while TNFAIP3 mutations were detected in 3% (1/32) of PCNSL. In PCNSL, all CARD11 mutations were heterozygous, in-frame, induced amino acid exchanges, and presumably led to activation of this oncogene. Spinal DLBCL harbored mutations of CARD11 and TNFAIP3 in 10% (1/10) and 20% (2/10) of cases, respectively. In both PCNSL and spinal DLBCL, mutations in CARD11 and TNFAIP3 were mutually exclusive. TNFAIP3 was unmethylated in all PCNSLs (30/30) and spinal DLBCLs (10/10). We conclude that mutations of the oncogene CARD11 may contribute to NF-kappa B activation and thereby play a role in the pathogenesis of PCNSL, while, in contrast to systemic DLBCL, inactivation of TNFAIP3 either by mutation or methylation seems to be of minor significance.

• 出版日期2010-10